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ABSTRACT
Glioblastoma is a devastating CNS tumour for which no cure is presently available. 
We wondered if manipulation of Emx2, which normally antagonizes cortico-cerebral 
astrogenesis by inhibiting proliferation of astrocyte progenitors, may be employed to 
counteract it. We found that Emx2 overexpression induced the collapse of seven out 
of seven in vitro tested glioblastoma cell lines. Moreover, it suppressed four out of 
four of these lines in vivo. As proven by dedicated rescue assays, the antioncogenic 
activity of Emx2 originated from its impact on at least six metabolic nodes, which 
accounts for the robustness of its effect. Finally, in two out of two tested lines, the 
tumor culture collapse was also achieved when Emx2 was driven by a neural stem cell-
specific promoter, likely active within tumor-initiating cells. All that points to Emx2 as 
a novel, promising tool for therapy of glioblastoma and prevention of its recurrencies.
INTRODUCTION
Emx2 is a transcription factor gene controlling a 
variety of brain developmental subroutines [1]. It cooperates 
with Otx2 and Pax6 in promoting formation and proper 
rostro-caudal specification of prosomeres 1-4, respectively 
[2]. Together with Pax6, it specifies dorsal telencephalon 
as pallium [3]. Within the early developing pallium, it 
stimulates the expansion of the neural precursor pool by 
delaying neuronogenesis progression [4] and the proper 
generation/survival of Cajal-Retzius pioneer neurons [5]. 
Moreover, it promotes the development of hippocampal and 
visual territories [6, 7].
Recently, we found that Emx2 also inhibits 
astrogliogenesis, by decreasing proliferation of astrocyte-
committed progenitors via EgfR and Fgf9 downregulation 
[8, 9]. Furthermore, several groups reported an inverse 
correlation between EMX2 expression levels and malignancy 
of a number of non neural tumors [10–14]. These findings 
led us to hypothesize employing Emx2 as a tool to suppress 
highly proliferating glioblastoma multiforme tumors (GBM).
GBM, also classified as WHO grade IV glioma, 
is the most aggressive malignant primary brain tumor in 
humans. It can affect cerebral cortex, cerebellum, brainstem 
and spinal cord. It mainly appears around 65-75 years, as a 
primary tumor or a recurrency of a previous, lower-grade 
glioma. Neurological symptoms are highly heterogeneous. 
Final prognosis is very poor. State of the art treatment 
combines surgery, temozolomide (TMZ) chemotherapy and 
radiation. Median survival upon this treatment is 14 months 
(only 4 in the absence of treatment) [15, 16].
GBMs are characterized by high mitotic rates, 
diminished apoptosis, poorly differentiated astrocytes 
and rich neoangiogenesis. Despite these commonalities, 
their origin and genetic features are highly heterogeneous. 
Nevertheless, GBMs (in particular, advanced/recurrent 
ones) share specific structural mutations and copy number 
variations, among which EGFR and PDGFRA amplification, 
as well as NF1, PTEN and CDKN2A/B loss [17].
Here we show that, in all GBM lines tested, Emx2 
overexpression suppresses glioblastoma growth, both in 
vitro and in vivo. Interestingly, Emx2 activity relies on 
modulation of a number of malignancy-related genes, 
including a subset of those affected in GBM by late, 
oncogenic copy number variations. This may result into 
an appreciable therapeutic effect on a large variety of 
GBMs and prevent selection of drug-resistant clones as 
well as recurrencies. Finally, Emx2 overexpression driven 
by the stem-cell-specific “neuro-Nestin promoter” [8] 
is still able to fully suppress tumor cultures. Therefore, 
this approach might be appropriate to target GBM cells 
while not damaging differentiated not-cancerous cells, and 
adequate to eradicate tumor-initiating-cells, so preventing 
GBM recurrencies.
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RESULTS
Emx2 overexpression kills glioblastoma cells 
in vitro
To assess if Emx2 can antagonize glioblastoma 
multiforme, we overexpressed its coding sequence in 2 
GBM lines (U87MG and T98G) as well as in GBM cell 
cultures originating from 5 different patients (GbmA, 
GbmB, GbmC, GbmD and GbmE), via lentiviral vectors 
and TetON technology. As controls, we employed the 
corresponding GBM cultures, infected by Egfp- or 
Emx2-encoding lentiviruses and kept in the presence or 
absence of doxycycline, respectively (Figure 1A, 1B and 
Supplementary Figure S1). In all cases, the activation of the 
Emx2 transgene arrested the expansion of the culture and 
led to its collapse, usually within 7-8 days, never beyond 
the 22nd day (Figure 1C-1I). As we detected in Emx2-gain 
of function (-GOF) GbmA, GbmB and GbmC samples 
(Figure 1L-1O), this possibly reflected a decrease of the 
proliferating fraction (up to -34.5±5.3%, p<0.01, in GbmB) 
(Figure 1L, 1M) and an increase of the apoptotic fraction 
(up to 539.7±90.5%, p<0.001, in GbmB) (Figure 1N-1O). 
Intriguingly, G1-to-S phase progression was not affected 
(Supplementary Figure S2).
Emx2 antagonizes glioblastoma by a pleiotropic 
impact on malignancy-related processes
To cast light on molecular mechanisms underlying 
Emx2 impact on GBM kinetics, we overexpressed its 
coding sequence in 5 GBM samples and scored mRNA 
levels of selected genes involved in their malignancy. 
These genes include: (a) a group implicated in relaying 
mitogenic signals along RTK cascades (EGFR, PDGF, 
PDGFRA, PTEN, NF1), (b) a group involved in the 
control of early G1/late G1 checkpoint (MYC, MYCN, 
RB1, CDKN2A, CDKN2B, CDK4, CDK6, CCND2), and 
(c) a more heterogeneous group dealing with a variety of 
malignancy-related processes, such as stemness, apoptosis, 
neovasculogenesis (SOX2, HES1, GLI1, TRP53, MDM2, 
VEGF). In all samples analyzed, Emx2 significantly 
altered the expression of group (a) genes, consistently 
with its antioncogenic activity. It downregulated EGFR in 
all cases. In addition, it decreased PDGF and PDGFRA 
in 1 and 4 cases, respectively, and increased PTEN, 
in 1 case (Table 1). In a large subset of samples, Emx2 
also modulated mRNA levels of group (b) genes, again 
in agreement with its antioncogenic activity (Table 1). 
These genes include - in particular - CDK4 and CDK6, 
mastering the early G1 checkpoint (decreased in 3 and 2 
cases, respectively). Finally, Emx2 downregulated SOX2 
in 4 samples and increased TRP53 and HES1 expression, 
in 2 and 5 samples, respectively (Table 1).
To complement mRNA profiling, we also monitored 
Emx2 overexpressing GBM cells for key phospho-proteins 
involved in malignancy-related, intracellular signal 
transduction (Figure 2 and Supplementary Figure S3). 
We found a significant decrease of p(Thr202/Tyr204)Erk1/2 
(-40.3±6.3%, p<0.005, see Figure 2C, 2D). This may 
stem from depressed EGF and PDGF signalling. It may 
be a key determinant of the kinetic behaviour of Emx2-
GOF GBM cells [16]. Furthermore, we detected a robust 
increase of p(Ser463/465)Smad1,5,8 (+100%, p<0.003, 
see Figure 2E, 2F). This is an index of enhanced Bmp 
signalling, which was shown to be instrumental to Emx2-
dependent inhibition of astroblast proliferation [9]. Finally, 
we found that Stat3 phosphorylation levels in Tyr705 and 
Ser727, crucial to self-renewing abilities of GBM cells [18], 
were unchanged (Figure 2G-2J).
Next, we tested the functional relevance of selected 
mRNA/protein changes described above to the Emx2 
antioncogenic activity. For this purpose, we chose a few 
“X” agents neutralizing such changes and evaluated their 
capability to rescue the original GBM kinetic profiles 
(Figure 3A-3C).
First, we tried to restore the basic expansion rate 
of GbmA and GbmC cultures, previously made gain-of-
function for Emx2, by transducing them with an EGFR-
expressing transgene (Figure 3A, rescue X1). This 
manipulation slowed down the decline of these cultures, 
however only in a partial and temporary fashion (Figure 
3D, 3G). A similar effect was elicited by overexpression of 
the stemness-factor SOX2 (Figure 3A, rescue X2) in Emx2-
GOF GbmA and GbmC (Figure 3E, 3H). Noticeably, 
neither EGFR nor SOX2 overexpression perturbed GBM 
kinetics in control conditions (Figure 3D, 3E, 3G, 3H).
Moreover, we tried to counteract HES1, one of 
the main Emx2-responders, whose overexpression was 
previously linked to proliferation arrest in a variety of 
contexts [19–21]. To this aim, we delivered its established 
functional antagonist HES6 [22] to GBM cells (Figure 3A, 
rescue X3). This manipulation slowed down the collapse 
of GbmA and GbmC cultures overexpressing Emx2, 
while not fully preventing it (Figure 3F, 3I). Conversely, 
HES6 overexpression did not promote GBM expansion in 
control conditions (Figure 3F, 3I).
Next, we tried to restore RTK signalling defects 
evoked by Emx2 (Figure 2C, 2D), providing GBM cultures 
with an excess of Fgf9 (Figure 3A, rescue X4). This is a key 
ligand down-regulated by Emx2 [9] and proven to promote 
proliferation within the astrocytic lineage [23]. Also, we 
silenced BMP signalling (Figure 3A, rescue X5), already 
proposed as a key therapeutic tool against GBM [24, 25]. 
Both manipulations slowed down the decline of Emx2-GOF 
GbmA cultures, however only to a partial extent (Figure 3J, 
3K). Neither Fgf9 nor BMP-inhibitor delivery promoted an 
expansion of control GbmA cells (Figure 3J, 3K).
Finally, in addition to Emx2 impact on transcription, 
we considered the possibility that the anti-oncogenic activity 
of this protein could be strenghtened by its capability to 
chelate the translational factor Eif4e [26]. In agreement with 
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Figure 1: Population dynamics of Emx2 gain-of-function GBM cultures. In vitro kinetic progression of U87MG, T98G, GbmA, 
GbmB, GbmC, GbmD and GbmE GBM lines C-I., engineered by lentiviral vectors and TetON technology as in A, B., and kept as adherent 
C, D. or floating cultures E-I., under Fgf2 and Egf. Ki67+ proliferating L, M. and activated-Casp3+ apoptotic N, O. fractions of GbmA, 
GbmB and GbmC glioblastoma cells, engineered by control (J., a-b1) and Emx2-GOF (J, a-b2) lentiviral sets, and kept as floating cultures 
according to the timetable in K. Cell numbers were normalized against t=0 values (C-I), or control values L, N. [As for (L, N), absolute 
average control cell frequencies were: 0.207, 0.155 and 0.131 (Ki67+, in GbmA, GbmB and GbmC cultures, respectively); 0.001, 0.012 and 
0.012 (actCasp3+, in GbmA, GbmB and GbmC cultures, respectively)]. n is the number of biological replicates. p-value was calculated by 
t-test (one-tail, unpaired): *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, *****p<0.00001.
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Table 1: Biased mRNA profiling of Emx2 gain-of-function GBM cultures
t
Gbm A Gbm B Gbm C Gbm D U87-MG
ge
ne
 
fu
nc
tio
n
3d 3d 3d 3d 4d
EGFR 0.25 ±0.06n=4,4; p<0.03
0.78 ±0.03
n=4,4; p<0.05
0.61 ±0.04
n=4,4; p<0.001
0.37 ±0.13
n=4,4; p<0.02
0.48 ±0.02
n=4,4; 
p<0.0005
R
T
K
 si
gn
al
in
gPDGF 0.40 ±0.004n=4,4; p<0.03 ns ns
1.74 ±0.12
n=4,4; p<0.002 ns
PDGFRA ns 0.75 ±0.11n=4,4; p<0.05
0.80 ±0.07
n=4,4; p<0.04
0.55 ±0.01
n=4,4; 
p<0.0001
0.16 ±0.10
n=4,4; 
p<0.0001
PTEN ns 1.54 ±0.23n=4,4; p<0.05 ns
0.30 ±0.03
n=4,4; p<0.01 ns
NF1 ns ns ns 0.26 ±0.01n=3,3; p<0.009 ns
MYC ns ns ns 0.83 ±0.04n=4,4; p<0.04 ns
ce
ll 
cy
cl
e 
co
nt
ro
l
MYCN 0.55 ±0.03n=3,3; p<0.02 ns ns
0.40 ±0.06
n=4,4; p<0.01 ns
RB1 ns 0.45 ±0.16n=4,4; p<0.02 ns
0.46 ±0.04
n=4,4; p<0.004 ns
CDKN2A ns 2.68 ±0.37n=4,4; p<0.01 ns
0.22 ±0.01
n=4,4; p<0.02 ns
CDKN2B ns 2.68 ±0.37n=4,4; p<0.01 ns
0.22 ±0.01
n=4,4; p<0.02 ns
CDK4 0.48 ±0.07n=3,3; p<0.005 ns ns
0.81 ±0.06
n=4,3; p<0.02
0.72 ±0.08
n=4,4; p<0.02
CDK6 0.30 ±0.02n=3,3; p<0.01 ns ns
0.36 ±0.004
n=4,3; p<0.002 ns
CCND2 0.16 ±0.06n=3,3; p<0.04 ns ns
1.17 ±0.03
n=4,4; p<0.005 ns
SOX2 0.30 ±0.04n=4,4; p<0.02
0.60 ±0.06
n=4,4; p<0.03
0.70 ±0.11
n=4,4; p<0.04
0.19 ±0.01
n=4,4; 
p<0.00001
ns
ot
he
r 
m
al
ig
na
nc
y-
re
la
te
d
HES1 2.56 ±0.37n=3,3; p<0.008
8.02 ±0.27
n=4,4; 
p<0.0001
1.38 ±0.05
n=4,4; p<0.001
1.28 ±0.02
n=4,4; p<0.02
4.34 ±0.80
n=4,4; p<0.004
GLI1 ns 2.60 ±0.65n=4,4; p<0.05 ns
2.90 ±0.25
n=4,4; p<0.001 ns
TRP53 ns 2.87 ±0.57n=4,4; p<0.008
4.58 ±0.87
n=3,3; p<0.01
0.67 ±0.05
n=4,4; p<0.001
0.66 ±0.08
n=4,4; p<0.04
MDM2 ns ns ns 0.46 ±0.06n=4,3; p<0.03 ns
VEGF ns ns ns ns ns
mRNA levels of presumptive mediators of Emx2 anti-oncogenic activity in GBM cells engineered as in Figure 1A. 
Seven days after lentiviral transduction, doxycyclin was added at 2 μg/ml. RNA samples were collected at time “t” after 
doxycyclin addition. qRT-PCR results, normalized against GAPDH and further normalized against their own negative 
controls, are shown as average ± s.e.m. Values possibly accounting for Emx2 anti-oncogenic activity are highlighted in blue. 
ns, not significant. n is the number of biological replicates. p-value was calculated by t-test (one-tail, unpaired).
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Figure 2: Immunoprofiling of Emx2 gain-of-function GBM cultures for key intracellular signalling transducers. 
Evaluation of p(Thr202/Tyr204)Erk1/2 C, D., p(Ser463/Ser465)Smad1/5/8 E, F. p(Tyr705)Stat3 G, H. and p(Ser727)Stat3 I, J. levels in U87 cell 
samples, engineered as in A, B. Values were normalied against controls. n is the number of biological replicates. p-value was calculated by 
t-test (one-tail, unpaired): *p<0.05, **p<0.01.
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Figure 3: Rescue of Emx2 antioncogenic activity via modulation of its presumptive mediators. GBM cells were engineered 
and cultured as in A-C. In particular, lentiviruses harboring an IRES-EGFP or a PLAP module under the control of a TREt promoter 
were used as controls for “b” and “X1, X2, X3, X6”, respectively. Cells were scored for the capability of selected “X” agents (restoring 
presumptive mediators of Emx2 anti-oncogenic activity) to rescue their control kinetic profiles D-L. n is the number of biological replicates. 
p-value was calculated by t-test (one-tail, unpaired).
this prediction, Eif4e overexpression in Emx2-GOF U87MG 
cultures (Figure 3A, rescue X6) delayed their decline, while 
not affecting U87MG controls (Figure 3L).
All that suggests that Emx2 may act by perturbing 
a number of genes and metabolic nodes crucial to 
GBM aggressiveness. It points at Emx2 as a promising 
therapeutic tool to simultaneously attack a variety of key 
effectors of GBM malignancy.
Emx2 overexpression elicits GBM collapse 
in vivo
To assess the portability of Emx2 antioncogenic 
activity in vivo, we transplanted engineered GBM cells 
(U87MG, GbmA, GbmC and GbmD) into the neocortical 
parenchyma of P4 wild-type mouse pups. Specifically, 
we injected a 1:1 mix of cells, made alternatively gain-
of-function for Emx2 or a control, and labelled with Egfp 
and mCherry, respectively. One week later, we sacrificed 
the animals and scored each brain for the ratio between 
the number of Emx2-GOF cells (Egfp+) and the number 
of control cells (mCherry+). This ratio was equal to 
0.40±0.05 (p<0.099, n=3), 0.44±0.13 (p<0.049, n=4), 
0.34±0.12 (p<0.025, n=4) and 0.29±0.04 (p<0.006, n=4), 
for U87MG, GbmA, GbmC and GbmD, respectively. This 
indicates that Emx2 exerts a robust antioncogenic activity 
even in vivo (Figure 4). (In a previous pilot test run with 
Egfp+ and mCherry+ GBM cells not harboring additional 
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Figure 4: Emx2 antioncogenic activity in vivo. Experimental strategy and employed lentiviral vectors are shown in A, B. A 1:1 
mix of differently fluoro-labelled, Emx2-GOF and control engineered GBM cells was transplanted into the cortical parenchyma of P4 wild 
type mouse pups. One week later, engrafted cells of different genotypes were scored in every single brain C-F'. 3-4 different brains were 
analyzed for every GBM line tested. p-value was calculated by t-test (one-tail, paired).
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transgenes, this ratio was close to 1) (Supplementary 
Figure S4).
Disappontingly, Emx2 overexpression in pyramidal 
neurons is highly toxic (our unpublished data). Therefore, 
generalized Emx2 delivery to the diseased brain of GBM 
patients would not be a suitable approach. To circumvent 
this issue, we thought to restrict therapeutic Emx2 
overexpression to tumor precursor cells, by putting it 
under the control of a cis-active element selectively firing 
in neural stem cells (Figure 5A, “Nes-p”; Supplementary 
Figure S5). Remarkably, this design turned out to be 
feasible, as it successfully replicated the kinetic outcome 
elicited upon generalized Emx2 overexpression (compare 
Figure 5C, 5D and Figure 1E, 1F).
DISCUSSION
Here we showed that Emx2 overexpression in a 
number of GBM cultures forced them to collapse, by 
promoting cell death and inhibiting cell proliferation. 
Emx2 impact on GBM metabolism was complex 
and a number of genes and pathways sensitive to its 
overexpression were co-involved in its antitumoral 
activity. Remarkably, such activity was confirmed in vivo, 
upon transplantation of conditionally engineered tumor 
cells into the neocortical parenchyma of mouse neonates. 
Last but not least, restricting Emx2 overexpression to 
presumptive tumor stem cells replicated the outcome of 
generalized gene overexpression.
Multiple bodies of correlative data suggest that 
EMX2 downregulation could contribute to the genesis 
of GBMs. The COSMIC database (http://cancer.sanger 
.ac.uk/cosmic) reports two distinct homozygous EMX2 
deletions occurring in 2 out of 801 gliomas (data not 
shown). Analysis of Allen Brain - Ivy Glioblastoma Atlas 
data showed us that EMX2-mRNA levels are specifically 
reduced by ≥2-folds in GBM tumors with respect to 
surrounding tissue (Supplementary Figure S6). Next, in the 
majority of glioblastoma cultures analyzed in the present 
study, endogenous EMX2-mRNA was undetectable. When 
it was present, its level was lower than in astrogenic, fetal 
cortico-cerebral NSCs (Supplementary Figure S7). Finally, 
a consistent scenario was found in acutely immunopanned 
GBM astrocytes, compared to astrocytes purified from 
the surrounding healthy tissue [27]. Albeit intriguing, 
all these correlative data are obviously not sufficient 
to draw firm conclusions about EMX2 role in GBM 
etiopathogenesis, which was out of the aims of the present 
study. Nevertheless, our data suggest that, regardless of its 
role in the oncogenic process, Emx2 may be a powerful 
tool for counteracting GBM tumors.
Subject of this study were two established GBM 
cell lines (U87MG and T98G) and five tumor cultures 
derived from operated GBM patients. Promisingly, all of 
Figure 5: Persisting antioncogenic efficacy of Emx2 upon neural nestin enhancer-restricted overexpression. In vitro 
kinetic progression of GbmA and GbmB lines C, D., engineered by lentiviral vectors and TetON technology as in A, B., and kept as floating 
cultures, under Fgf2 and Egf. Cell numbers were normalized against t=0 values. n is the number of biological replicates. p-value was 
calculated by t-test (one-tail, unpaired): ***p<0.001, ****p<0.0001.
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them robustly responded to Emx2 and rapidly collapsed, 
because of defective proliferation and exaggerated cell 
death (Figure 1 and Supplementary Figure S2).
Noticeably, their molecular responses were 
complex and not stereotyped (Table 1), possibly reflecting 
GBM etiopathogenetic heterogeneity [28, 17, 29]. The 
vast majority of molecular changes evoked by Emx2 
were consistent with its antitumor activity (Table 1 
and Figure 2), a selection of them was proven to be 
instrumental to it (Figure 3). However, in no case, 
counteracting each of these changes could fully restore 
original kinetic properties of the cultures (Figure 3). 
All this means that Emx2 antioncogenic efficacy may 
emerge as a consequence of its ability to attack a variety 
of metabolic nodes crucial to malignancy. In addition to 
a robust inhibition of GBM expansion, this ability might 
help preventing selection of drug-resistant clones and 
recurrencies. Intriguingly, a number of Emx2-repressed 
and -stimulated genes reported above are the very same 
affected by duplications and deletions in late stage glioma 
cancers, respectively [17]. This further suggests that 
our manipulation could be therapeutically effective on a 
variety of high grade gliomas, regardless of their primary 
molecular origin.
Remarkably, Emx2 overexpression elicited a 
pronounced anti-GBM activity even in vivo (Figure 4). 
This was found by cotransplanting conditionally engineered 
tumor cells, alternatively expressing Emx2 or a control 
transgene, into the cortical parenchyma of wild type 
mouse pups and scoring the outcome one week later. This 
is a novel experimental setup, allowing to preliminarly 
assess antioncogenic power in vivo, quickly, in an 
immunocompetent environment, and in the presence of 
strong progliogenic cues. Finally, of particular therapeutic 
interest is the fact that a collapse of engineered GBM 
cultures also occurred when Emx2 overexpression was 
restricted to Nes-p+ precursor cells (Figure 5). These cells, 
in fact, are likely to include tumor initiating cells (TICs), 
from which tumor recurrencies are supposed to originate 
[38]. Such cells may escape even the attack by the most 
advanced oncolytic vectors developed against GBM [39].
All these results point to Emx2 as a novel, promising 
tool for GBM therapy. However, for this purpose long-
term survival tests as well as the selection of a more 
appropriate, not-genotoxic vectors for gene delivery, 
are mandatory. Moreover, an in depth exploration of 
mechanisms mediating Emx2 activity, by unbiased GBM 
transcriptome profiling, is also due. These issues will be 
hopefully subject of a dedicated follow-up study.
MATERIALS AND METHODS
Lentiviral vectors packaging and titration
All lentiviruses were generated and titrated as 
previously described [40]. The full list of genomic plasmids 
used for lentiviruses packging is reported in Supplementary 
Materials.
GBM cell culture
Human U87MG GBM cell line (derived from 
a malignant glioma from a female patient by explant 
technique; PCR-validated as follows: Amelogenin: X; 
CSF1PO: 10,11; D13S317: 8,11; D16S539: 12; D5S818: 
11,12; D7S820: 8,9; THO1: 9.3; TPOX: 8; vWA: 15,17) 
and T98G GBM cell line (derived from glioblastoma 
multiform tumour from a 61-year-old Caucasian male; 
PCR-validated as follows: Amelogenin: X,Y; CSF1PO: 
10,12; D13S317: 13; D16S539: 13; D5S818: 10,12; 
D7S820: 9,10; THO1: 7,9.3; TPOX: 8; vWA: 17,20) were 
purchased from SIGMA (#89081402 and #92090213, 
respectively). Low passage criopreserved samples of 
them were employed to run this analysis. They were 
kept as adherent cultures in DMEM/Glutamax medium 
(ThermoFisher, Waltham - MA, #31966), supplemented 
with 10% FBS and 1X Pencillin/Streptomycin. Cells were 
cultured at 500 cells/μl and passaged by trypsin on days of 
counting or, at most, every 4 days.
GbmA-E cells originate from GBM surgical samples 
collected at IRCCS A.O.U. San Martino-IST, Dept of 
Neuroscience and Sense organs, Unit of Neurosurgery 
and Neurotraumatology, with patients' informed consent 
and in compliance with pertinent Italian law. They were 
derived in AD laboratory. Low passage criopreserved 
samples of them were employed in AM laboratory to 
run this analysis. GbmA cells were cultured in “DMEM 
/ F12 / glutamax / NeurobasalA” (ThermoFisher #10888-
022). GbmB-E were cultured as spheres in NeuroCult™ 
NS-A Proliferation Kit (Human) (StemCell Technologies, 
Vancouver - Canada, #05751). In both cases, mediums 
were supplemented with 1X Penicillin/Streptomycin, 2 
μg/ml human heparin (StemCell Technologies #07980), 
20 ng/ml recombinant human EGF (ThermoFisher 
#PHG0311), 20 ng/ml recombinant human FGF2 
(ThermoFisher #PHG0261). All the cells were cultured 
under normoxic conditions (5% CO2, 21% O2, 74% 
N2). Cells were cultured at 500 cells/μl and passaged 
by Accutase (Sigma, Milan - Italy, #A6964) on days of 
counting or, at most, every 4 days.
When required, cells were acutely infected, at 
a concentration of 500 cells/μl, by a mix containing 
lentiviral vectors, each one at a multiplicity of infection 
(m.o.i) = 6. This moi is sufficient to infect the almost 
totality of GBM cells in such conditions. Where required, 
they were subsequently transferred to polylysinated 
coverslips. In specific cases, medium was supplemented 
by 0.7 μM LDN193189 (Stemgent, Lexington - MA, 
#130-096-226), 20 ng/ml Fgf9 (Sigma #SRP4057-
10UG), or 10μg/ml BrdU. TetON-controlled transgenes 
were switched on by 2 μg/ml doxycyclin (Sigma #D9891-
10G). n is the number of biological replicates. p-value was 
calculated by t-test (one-tail, unpaired).
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Cell growth curves
After sphere dissociation, 2x105 GBM cells/well 
were seeded in a 24-well plate and infected with LV_
Pgk1p-rtTA-M2-WPRE and LV_TREt-IRES-EGFP-
WPRE or LV_TREt-Emx2-IRES-EGFP-WPRE, each 
at m.o.i. 6. Viable cells (trypan blue-excluding) were 
counted at fixed days on a hemocytometer. After every cell 
count, differently engineered cells were plated at the same 
concentration (2 × 105 GBM cells/well). Cell counting was 
performed on 1/200 of each biological sample (in case 
of Figure 1, 3 and 5 data, at t=0, each sample included 
200,000 cells). Growth curves were interrupted when 
Emx2-GOF cell cultures had collapsed.
mRNA profiling
Aliquots of 2*105 GBM cells were infected with a 
lentivector mix containing LV_Pgk1p-rtTA-M2-WPRE 
and LV_TREt-IRES-EGFP-WPRE or LV_TREt-Emx2-
IRES-EGFP-WPRE, each at m.o.i. 6. Seven days after 
infection, 2 μg/ml doxycycline was added. Three or four 
days later, cell pellets were processed for RNA extraction 
by Trizol™ (ThermoFisher #15596-026). Agarose gel 
electrophoresis and spectrophotometric measurements 
(NanoDrop ND-1000) were employed to estimate quantity, 
quality and purity of the resulting RNA. Prior to analysis, 
samples were processed by the TurboDNAfree kit 
(ThermoFisher #AM1907), according to manufacturer's 
instructions.
At least 1.0 μg RNA from each sample was 
retrotranscribed by SuperScriptIII™ (ThermoFisher 
#18080044) in the presence of random hexamers, 
according to manufacturer's instructions. RT-minus 
samples were scored as controls, in the case of intronless 
transcripts.
1/50 of the resulting cDNA was used as substrate 
of any subsequent qPCR reaction. PCR reactions were 
performed by the SybrGreen™ platform (Biorad, Milan - 
Italy, #1725270), according to manufacturer’s instructions.
The full list of primers is reported in Supplementary 
Materials and Methods.
Each biological replicate was scored at least in 
technical triplicate and data were normalized against 
GAPDH. Results were averaged and further normalized on 
their controls. Averages ± s.e.m.'s were reported in Table 1. 
Statistical significance of results was evaluated by the 
t-test (one-tail; unpaired). “n” is the number of samples.
Western blots
Western analysis was performed according to 
standard methods. Total cell lysates in CHAPS buffer 
were quantified by BCA protein assay kit (ThermoFisher 
#10678484) and denatured at 95°C for 5 min, prior to 
loading. Thirty micrograms of proteins were loaded per 
each lane and run on a 12% acrylamide − 0.1% SDS gel.
Full details about antibodies employed are reported 
in Supplementary Materials and Methods. Different 
antigens and bACT were sequentially revealed by an ECL 
kit (GE Healthcare, Milan - Italy, #GERPN2109). Images 
were acquired by an Alliance LD2–77.WL apparatus 
(Uvitec, Cambridge) and analyzed by Adobe Photoshop 
CS2 software™ and Microsoft Excel 11 software™.
Animal handling
Animal handling and subsequent procedures were 
in accordance with European [European Communities 
Council Directive of November 24, 1986 (86/609/
EEC)] and Italian laws (D.L. 04.03.2014, n°26) and were 
approved by SISSA Board for Animal Welfare. Wild type 
mice (strains CD1 purchased from Harlan-Italy) were 
maintained at the SISSA mouse facility. P0 stands for the 
animal birthday.
Cell transplantation
P4 pups were anaesthetized on ice for 40-60s. 2.0 
μl of a solution containing 200,000 cells (100,000 Emx2-
GOF-Egfp+ and 100,000 control-mCherry+ cells, pre-
engineered by lentiviral transduction 1 week before), 
mixed with 0.02% fast-green dye in NeuroCult™ NS-A 
Proliferation (Human) medium (StemCell Technologies 
#05751), were injected through the skull into the 
corticocerebral parenchyma, by free hands, using a sharp 
pulled micropipette (hole external diameter about 40 μm) 
with the help of light fibers. Animals were left to recover 
in a warm clean cage. Then they were transferred to their 
mother and were finally sacrificed 7 days later.
Sample preparation for immunofluorescence
As for the brains, they were fixed by immersion in 
4% PFA overnight at 4°C, washed by 1X PBS 3 times, 
equilibrated in 30%sucrose-1XPBS at 4°C, included 
into OCT (Killik) and frozen at -80°C. Finally they were 
coronally sliced at 16 μm, by a Microm cryostat.
As for dissociated cell cultures, they were acutely 
attached on coverslips, fixed in 4% PFA for 15 min at 
room temperature and washed by 1X PBS 3 times.
Immunofluorescence
Immunocytofluorescence was performed as 
previously described [8, 41]. Specifically, BrdU unmasking 
was performed by 0.2 M HCl, for 15 min at RT. The full 
list of antibodies employed is reported in Supplementary 
Materials and Methods.
Immunos were photographed on a Nikon Eclipse 
TI microscope equipped with a 20X objective and a 
Hamamatsu camera. Images were imported and analyzed 
by Photoshop CS2 (Adobe) software. Where not otherwise 
stated, each experiment was performed at least in 
biological triplicate.
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For each dissociated cell culture sample, cells were 
counted from at least 20 randomly assorted photographic 
fields, by an operator blind of sample identity. As for Ki67 
and BrdU quantification, 2,000 cells/sample were scored. 
As for actCasp3 quantification, 10,000, 2,000 and 2,000 
cells/sample were scored, in case of GbmA, -B and -C 
cultures, respectively. Frequencies of immunoreactive cells 
were averaged and s.e.m.'s were calculated. Results were 
normalized against controls. Their statistical significance 
was evaluated by the t-test (one-tail; unpaired). “n” is the 
number of samples.
Pictures of transplanted brains were electronically 
encrypted by random inversion of green and red signals 
and analyzed by an operator blind of sample identity. 
For each brain, tumor cells were counted from 1 every 5 
sections and total, Egfp+ and mCherry+ cell numbers were 
plotted. Statistical significance of results was evaluated by 
the t-test (one-tail; paired). “n” is the number of samples.
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